» Articles » PMID: 32392911

Interaction of Promyelocytic Leukemia/p53 Affects Signal Transducer and Activator of Transcription-3 Activity in Response to Oncostatin M

Overview
Specialty Pharmacology
Date 2020 May 13
PMID 32392911
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Promyelocytic leukemia () gene, through alternative splicing of its C-terminal region, generates several PML isoforms that interact with specific partners and perform distinct functions. The PML protein is a tumor suppressor that plays an important role by interacting with various proteins. Herein, we investigated the effect of the PML isoforms on oncostatin M (OSM)-induced signal transducer and activator of transcription-3 (STAT-3) transcriptional activity. PML influenced OSM-induced STAT-3 activity in a cell type-specific manner, which was dependent on the p53 status of the cells but regardless of PML isoform. Interestingly, overexpression of PML exerted opposite effects on OSM-induced STAT-3 activity in p53 wild-type and mutant cells. Specifically, overexpression of PML in the cell lines bearing wild-type p53 (NIH3T3 and U87-MG cells) decreased OSM-induced STAT-3 transcriptional activity, whereas overexpression of PML increased OSM-induced STAT-3 transcriptional activity in mutant p53-bearing cell lines (HEK293T and U251-MG cells). When wild-type p53 cells were co-transfected with PML-IV and R273H-p53 mutant, OSM-mediated STAT-3 transcriptional activity was significantly enhanced, compared to that of cells which were transfected with PML-IV alone; however, when cells bearing mutant p53 were co-transfected with PML-IV and wild-type p53, OSM-induced STAT-3 transcriptional activity was significantly decreased, compared to that of transfected cells with PML-IV alone. In conclusion, PML acts together with wild-type or mutant p53 and influences OSM-mediated STAT-3 activity in a negative or positive manner, resulting in the aberrant activation of STAT-3 in cancer cells bearing mutant p53 probably might occur through the interaction of mutant p53 with PML.

Citing Articles

Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates.

Liebl M, Hofmann T Cancers (Basel). 2022; 14(19).

PMID: 36230470 PMC: 9558958. DOI: 10.3390/cancers14194549.

References
1.
Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

2.
Huang S . Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007; 13(5):1362-6. DOI: 10.1158/1078-0432.CCR-06-2313. View

3.
Kato M, Muromoto R, Togi S, Iwakami M, Kitai Y, Kon S . PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction. Biochem Biophys Res Commun. 2015; 461(2):366-71. DOI: 10.1016/j.bbrc.2015.04.040. View

4.
Oh W, Ghim J, Lee E, Yang M, Kim E, Ahn J . PML-IV functions as a negative regulator of telomerase by interacting with TERT. J Cell Sci. 2009; 122(Pt 15):2613-22. DOI: 10.1242/jcs.048066. View

5.
West A, Tsui V, Stylli S, Nguyen H, Morokoff A, Kaye A . The role of interleukin-6-STAT3 signalling in glioblastoma. Oncol Lett. 2018; 16(4):4095-4104. PMC: 6144698. DOI: 10.3892/ol.2018.9227. View